fbpx
Loading...

ANZGOG unveils 2023-2028 Strategic Plan – Advancing Research, Saving Lives

Introducing our new strategic plan, a five-year roadmap that will advance the excellence and impact of our gynaecological cancer research. In May 2023, a group of 24 ANZGOG members gathered to discuss the organisation's values, [...]

ANZGOG unveils 2023-2028 Strategic Plan – Advancing Research, Saving Lives2023-08-30T12:18:29+10:00

The Larapinta Trek team raises over $75,000 for gynaecological cancer research

More than an adventure, WomenCan's Larapinta trek symbolises the unity, and determination towards a critical cause - supporting ANZGOG's research. Three dedicated ANZGOG members: Professor Linda Mileshkin (Medical Oncologist, VIC), Associate Professor Jeffrey Goh (Medical [...]

The Larapinta Trek team raises over $75,000 for gynaecological cancer research2023-10-18T11:43:07+11:00

New global therapy now approved for Australian patients with Leiomyosarcoma

An additional chemotherapy option for people with advanced leiomyosarcoma is now available on the Pharmaceutical Benefits Scheme (PBS). Trabectedin, (brand name - Yondelis) offers renewed hope for patients facing this rare and challenging sarcoma cancer. [...]

New global therapy now approved for Australian patients with Leiomyosarcoma2023-10-18T11:44:07+11:00

PARAGON – the study that drove ANZGOG’s position at the forefront of innovative trial designs

Led by ANZGOG co-founder Professor Michael Friedlander AM, PARAGON was one of ANZGOG's first practice-changing studies. The publications arising from the insights and data collected because of this pivotal trial continue to contribute to research on [...]

PARAGON – the study that drove ANZGOG’s position at the forefront of innovative trial designs2023-10-18T11:45:30+11:00
Go to Top